Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL206973 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2SLC22A6KMT2AMAPTGABRR1 | |
| SCHEMBL222024 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2SLC22A6KMT2AMAPTGABRR1 | |
| Ammonia Solution, Strong SCHEMBL21219123 | 0.98 | SMN1; SMN2 (0.50) | SMN1; SMN2SLC22A6KMT2AMAPTGABRR1 | |
| SCHEMBL10933476 | 0.98 | SMN1; SMN2 (0.50) | SMN1; SMN2SLC22A6KMT2AMAPTGABRR1 | |
| Ethylene SCHEMBL5860683 | 0.95 | SMN1; SMN2 (0.48) | SMN1; SMN2SLC22A6KMT2AMAPTGABRR1 | |
| Acrylamide SCHEMBL28172860 | 0.84 | TSHR (0.39) | SMN1; SMN2SLC22A6KMT2AGABRR1LMNA | |
| SCHEMBL8627026 | 0.84 | SMN1; SMN2 (0.36) | SMN1; SMN2SLC22A6KMT2AMAPTTSHR | |
| SCHEMBL1691025 | 0.80 | TSHR (0.43) | SMN1; SMN2KMT2AMAPTTSHRCA1 | |
| SCHEMBL8060426 | 0.80 | ALDH1A1 (0.42) | SMN1; SMN2KMT2ALMNATDP1TSHR | |
| SCHEMBL1823637 | 0.80 | TSHR (0.43) | SMN1; SMN2KMT2AMAPTTSHRCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119968441-A | Conductive composition, sintered body, laminated structure, electronic component, and semiconductor device | 纳美仕有限公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11439993-B2 | Chiral binuclear metal complexes for stereoselective hydrolysis of saccharides and glycosides | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2022-09-13 | — | — | US | disclosed |
| CN-107949562-B | Positive allosteric modulators of muscarinic M2 receptors | 拜耳制药股份公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20210101138-A1 | CHIRAL BINUCLEAR METAL COMPLEXES FOR STEREOSELECTIVE HYDROLYSIS OF SACCHARIDES AND GLYCOSIDES | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2021-04-08 | — | — | US | disclosed |
| US-10870103-B2 | Chiral binuclear metal complexes for stereoselective hydrolysis of saccharides and glycosides | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2020-12-22 | — | — | US | disclosed |
| EP-3307741-B1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARIC M2 RECEPTOR | Bayer Pharma AG (DE) | 2020-10-28 | — | — | EP | disclosed |
| EP-3307741-B1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARIC M2 RECEPTOR | Bayer Pharma AG (DE) | 2020-10-28 | — | — | EP | disclosed |
| EP-3692991-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC M2 RECEPTOR | Bayer Pharma Aktiengesellschaft (DE) | 2020-08-12 | — | — | EP | disclosed |
| US-20150126566-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED | 2015-05-07 | — | — | US | disclosed |
| US-20150126566-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED | 2015-05-07 | — | — | US | disclosed |
| US-8299069-B2 | 2-(2-oxoindoline-3-ylidene)methyl-5-(2-hydroxy-3-morpholin-4-yl-propyl)-6,7-dihydro-1H-pyrrol[3,2-C]pyridine-4(5H)-one compounds and use as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2012-10-30 | — | — | US | disclosed |
| US-20100160317-A1 | 2-(2-OXOINDOLINE-3-YLIDENE)METHYL-5-(2-HYDROXY-3-MORPHOLIN-4-YL-PROPYL)-6,7-DIHYDRO-1H-PYRROL[3,2-C]PYRIDINE-4(5H)-ONE COMPOUNDS AND USE AS PROTEIN KINASE INHIBITORS | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2010-06-24 | — | — | US | disclosed |
| EP-0535192-B1 | NOVEL DNA GYRASE INHIBITORS, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME | HOFFMANN LA ROCHE (CH) | 1996-06-19 | — | — | EP | disclosed |
| US-5486466-A | ENZYME INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 1996-01-23 | — | — | US | disclosed |
| US-5399741-A | DNA gyrase inhibitors, process for their manufacture and pharmaceutical preparations containing same | HOFFMANN-LA ROCHE INC. (US) | 1995-03-21 | — | — | US | disclosed |
| US-5294609-A | Microbiocides | HOFFMANN-LAROCHE INC. (US) | 1994-03-15 | — | — | US | disclosed |
| EP-0535192-A1 | NOVEL DNA GYRASE INHIBITORS, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME. | HOFFMANN LA ROCHE (CH) | 1993-04-07 | — | — | EP | disclosed |
| WO-1992018490-A1 | NOVEL DNA GYRASE INHIBITORS, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME | F. HOFFMANN-LA ROCHE AG (CH) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160317-A1 | 2-(2-OXOINDOLINE-3-YLIDENE)METHYL-5-(2-HYDROXY-3-MORPHOLIN-4-YL-PROPYL)-6,7-DIHYDRO-1H-PYRROL[3,2-C]PYRIDINE-4(5H)-ONE COMPOUNDS AND USE AS PROTEIN KINASE INHIBITORS | DMPK, MAP4K2, PLK2 | SMN1; SMN2 2740/4885SLC22A6 4560/4885KMT2A 1140/4885 |
| US-20150126566-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, SCNN1G, SCNN1B | SMN1; SMN2 4838/4885SLC22A6 500/4885KMT2A 4375/4885 |
| US-10870103-B2 | Chiral binuclear metal complexes for stereoselective hydrolysis of saccharides and glycosides | MANBA, HEXB, GALE | SMN1; SMN2 4015/4885SLC22A6 1335/4885KMT2A 2635/4885 |
| US-20210101138-A1 | CHIRAL BINUCLEAR METAL COMPLEXES FOR STEREOSELECTIVE HYDROLYSIS OF SACCHARIDES AND GLYCOSIDES | MANBA, HEXB, GALE | SMN1; SMN2 4015/4885SLC22A6 1335/4885KMT2A 2635/4885 |
| US-11439993-B2 | Chiral binuclear metal complexes for stereoselective hydrolysis of saccharides and glycosides | MANBA, HEXB, GALE | SMN1; SMN2 4015/4885SLC22A6 1335/4885KMT2A 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.